Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $33 from $25 after the company received FDA clearance to start a Phase II/III trial of wholly-owned ARO-AAT in Alpha-1 antitrypsin deficiency. The analyst increased his value for ARO-AAT and reiterates an Overweight rating on Arrowhead shares.

Athira Pharma (ATHA) announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. San Martin joins Athira from Arrowhead Pharmaceuticals (ARWR), where he served as Chief Medical Officer and guided development teams to advance that company's RNAi-based therapeutics in the metabolic and liver disease area